The first US congressional committee hearing on the Trump Administration’s blueprint for lowering drug prices suggests that legislation is possible on a modest suite of reforms but that the most impactful changes may come from administrative action.
During the June 12 hearing in the Senate Health, Education, Labor and Pensions Committee, Health and Human Services (HHS) Secretary...